Each tablet contains Standardized Ginkgo biloba (EGB 761) containing 24% of Gingko glycosides and 6% of ginkgolides-bilobalide.
Excipients/Inactive Ingredients: Lactose monohydrate, microcrystalline cellulose, maize starch, anhydrous colloidal silica, talc, magnesium stearate, hypromellose, macrogol 400 and 6000, titanium dioxide, red iron oxide.
Pharmacotherapeutic Group: Peripheral Vasodilator (C: Cardiovascular system).
Pharmacology: Pharmacodynamics: The multiple mechanisms underlying the therapeutic effects have not to date been demonstrated in man.
Pharmacokinetics: The active ingredient is standardized Gingko biloba extract titrated at 24% with heterosides of Gingko and 6% of di and sesquiterpene (ginkgolides A, B and C bilobalide).
In man, only the pharmacokinetic parameters of the terpenic fraction have been highlighted.
The ginkgolides A and B and the bilobalide have an oral bioavailability of 80% to 90%. Maximum concentration is reached in 1 to 2 hours; the elimination half-lives last for around 4 hours (bilobalide, ginkgolide A) to 10 hours (ginkgolide B).
These substances are not broken down in the body and they are principally eliminated in the urine, and a small quantity excreted in the stools.
Arteriopathic Disease: Symptomatic treatment of intermittent claudication in chronic obliterating artheriopathies of the lower limbs.
Cerebral Vascular Disorder/Cognitive and Neurosensorial Deficit: Treatment aimed at symptomatic management of cognitive pathological and chronic neurosensorial deficit in the elderly patient with Alzheimer's disease and other dementia.
Hearing Troubles/Vertigo/Tinnitus: Secondary treatment of losses in auditive capacity and certain syndromes of vertigo and/or tinnitus presumed to be of vascular origin.
Visual Disorders: Secondary treatment of losses in acuity and troubles of the visual field presumed to be of vascular origin.
Others: Disturbances in skin circulation.
Recommended Dose: Follow the instructions of the prescribing physician.
Usual mean dosage: 1 tablet before meals, 3 times daily.
Administration: Oral route.
The tablets should be taken with a half-glass of water, during meals.
Hypersensitivity to one of the ingredients of the tablet.
Since Tanakan contains lactose, it is contraindicated in subjects presenting with congenital galactosemia, glucose or galactose malabsorption syndrome or with lactase deficiency.
Tanakan is mainly used for the the elderly, for whom the risk of pregnancy is non-existent.
In the absence of relevant clinical data, the use of this product is not recommended during pregnancy or breastfeeding.
Rarely, digestive disorders, skin disorders, headaches.
Store at cool and dry place, below 25°C.
N06DX02 - Ginkgo folium ; Belongs to the class of other anti-dementia drugs.
Tab 40 mg (film-coated) x 30's.